Clinical trial · Interventional
L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)
L-Carnitine in the Palliative Treatment of Advanced Pancreatic Cancer (CARPAN): a Prospective, Randomised, Placebo Controlled, Double Blinded, Multicentre Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): after interims analysis standard errors for inflammatory and nutritional markers varied widely, that the power calculation required unattainable goals
Summary
Brief summary (as posted)
The study investigated the role of L-Carnitine supplementation on proinflammatory immune response, malnutrition, cancer cachexia and cancer related fatigue in advanced and inoperable pancreatic cancer, UICC Stage IV .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Carcinoma | Pancreatic Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| L-Carnitine | Dietary Supplement | — | UNRESOLVED |
| Placebo | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- L-Carnitine
- description
- L-Carnitine 4 g daily for Intervention
- interventionNames
- Dietary Supplement: L-Carnitine
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo (tartaric acid)
- interventionNames
- Dietary Supplement: Placebo
Primary outcomes (1)
- measure
- TNF-alpha
- timeFrame
- 12 weeks
- description
- Influence of L-Carnitine on proinflammatory cytokine TNF-alpha
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * advanced pancreatic cancer (UICC Stage IV) * Karnofsky Index larger than 60 * compliance * consent to participate to the study Exclusion Criteria: * Child-Pugh classification of liver failure greater than Child B, * a known second malignant tumor * oral or parenteral supplementation with omega-3-fatty acids * treatment with thalidomide or Infliximab * mental or physical disorders
References
Publications (0)
Data not yet available